FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994201468> ?p ?o ?g. }

• W1994201468 endingPage "606" @default.
• W1994201468 startingPage "599" @default.
• W1994201468 abstract "With femoral access, bivalirudin decreases risks of major bleeding after percutaneous coronary intervention (PCI) and provides better net clinical benefit compared to unfractionated heparin (UFH) plus planned glycoprotein IIb/IIIa inhibitors. Whether this benefit exists compared to UFH monotherapy is less clear. We performed a systematic review and meta-analysis to compare outcomes in patients undergoing transfemoral PCI with UFH or bivalirudin. Randomized trials (n = 3) and observational studies (n = 13) comparing bivalirudin to UFH monotherapy were reviewed. Primary outcomes were 30-day rates of major adverse cardiovascular events (MACEs) including death, myocardial infarction (MI), urgent revascularization, as well as all-cause mortality, MI, major bleeding, and blood transfusion. We collected data from 16 studies involving 32,492 patients undergoing PCI. Most observational studies were performed in the United States, whereas all randomized trials were done in Europe. Compared to UFH monotherapy, bivalirudin was associated with similar risk of MACEs (odds ratios [OR] 0.92, 95% confidence interval [CI] 0.75 to 1.12), a substantial 45% relative decrease in major bleeding (OR 0.55, 95% CI 0.43 to 0.72), and a trend in the decrease of transfusion (OR 0.87, 95% CI 0.70 to 1.08). A decrease in mortality was seen in observational studies (OR 0.62, 95% CI 0.45 to 0.85) but remained inconclusive in randomized trials (OR 0.63, 95% CI 0.20 to 2.01). MI rate was similar with the 2 anticoagulants. In conclusion, in patients undergoing transfemoral PCI, the benefit of bivalirudin over UFH monotherapy is driven by a significant decrease in major bleeding with similar rates of MACE. As PCI practice moves toward other bleeding-avoidance strategies such as the radial approach, future studies should focus on the interaction between anticoagulant strategy and access-site choice. With femoral access, bivalirudin decreases risks of major bleeding after percutaneous coronary intervention (PCI) and provides better net clinical benefit compared to unfractionated heparin (UFH) plus planned glycoprotein IIb/IIIa inhibitors. Whether this benefit exists compared to UFH monotherapy is less clear. We performed a systematic review and meta-analysis to compare outcomes in patients undergoing transfemoral PCI with UFH or bivalirudin. Randomized trials (n = 3) and observational studies (n = 13) comparing bivalirudin to UFH monotherapy were reviewed. Primary outcomes were 30-day rates of major adverse cardiovascular events (MACEs) including death, myocardial infarction (MI), urgent revascularization, as well as all-cause mortality, MI, major bleeding, and blood transfusion. We collected data from 16 studies involving 32,492 patients undergoing PCI. Most observational studies were performed in the United States, whereas all randomized trials were done in Europe. Compared to UFH monotherapy, bivalirudin was associated with similar risk of MACEs (odds ratios [OR] 0.92, 95% confidence interval [CI] 0.75 to 1.12), a substantial 45% relative decrease in major bleeding (OR 0.55, 95% CI 0.43 to 0.72), and a trend in the decrease of transfusion (OR 0.87, 95% CI 0.70 to 1.08). A decrease in mortality was seen in observational studies (OR 0.62, 95% CI 0.45 to 0.85) but remained inconclusive in randomized trials (OR 0.63, 95% CI 0.20 to 2.01). MI rate was similar with the 2 anticoagulants. In conclusion, in patients undergoing transfemoral PCI, the benefit of bivalirudin over UFH monotherapy is driven by a significant decrease in major bleeding with similar rates of MACE. As PCI practice moves toward other bleeding-avoidance strategies such as the radial approach, future studies should focus on the interaction between anticoagulant strategy and access-site choice." @default.
• W1994201468 created "2016-06-24" @default.
• W1994201468 creator A5014032885 @default.
• W1994201468 creator A5018963320 @default.
• W1994201468 creator A5031742046 @default.
• W1994201468 creator A5032623848 @default.
• W1994201468 creator A5046856065 @default.
• W1994201468 creator A5046945534 @default.
• W1994201468 creator A5053058017 @default.
• W1994201468 creator A5063978497 @default.
• W1994201468 creator A5077517566 @default.
• W1994201468 date "2012-08-01" @default.
• W1994201468 modified "2023-10-16" @default.
• W1994201468 title "Meta-Analysis Comparing Bivalirudin Versus Heparin Monotherapy on Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention" @default.
• W1994201468 cites W165703145 @default.
• W1994201468 cites W1971519115 @default.
• W1994201468 cites W1979423827 @default.
• W1994201468 cites W2004110783 @default.
• W1994201468 cites W2004446092 @default.
• W1994201468 cites W2010936821 @default.
• W1994201468 cites W2011498879 @default.
• W1994201468 cites W2016844884 @default.
• W1994201468 cites W2019002307 @default.
• W1994201468 cites W2030271409 @default.
• W1994201468 cites W2060049024 @default.
• W1994201468 cites W206747855 @default.
• W1994201468 cites W2070261961 @default.
• W1994201468 cites W2078904498 @default.
• W1994201468 cites W2081047245 @default.
• W1994201468 cites W2083994815 @default.
• W1994201468 cites W2088834510 @default.
• W1994201468 cites W2093016542 @default.
• W1994201468 cites W2119218382 @default.
• W1994201468 cites W2143763771 @default.
• W1994201468 cites W2147482806 @default.
• W1994201468 cites W2150146686 @default.
• W1994201468 cites W2161094011 @default.
• W1994201468 cites W2162886513 @default.
• W1994201468 cites W2332614840 @default.
• W1994201468 cites W2468996569 @default.
• W1994201468 cites W2887180359 @default.
• W1994201468 doi "https://doi.org/10.1016/j.amjcard.2012.03.051" @default.
• W1994201468 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22591669" @default.
• W1994201468 hasPublicationYear "2012" @default.
• W1994201468 type Work @default.
• W1994201468 sameAs 1994201468 @default.
• W1994201468 citedByCount "37" @default.
• W1994201468 countsByYear W19942014682012 @default.
• W1994201468 countsByYear W19942014682013 @default.
• W1994201468 countsByYear W19942014682014 @default.
• W1994201468 countsByYear W19942014682015 @default.
• W1994201468 countsByYear W19942014682016 @default.
• W1994201468 countsByYear W19942014682017 @default.
• W1994201468 countsByYear W19942014682019 @default.
• W1994201468 countsByYear W19942014682020 @default.
• W1994201468 crossrefType "journal-article" @default.
• W1994201468 hasAuthorship W1994201468A5014032885 @default.
• W1994201468 hasAuthorship W1994201468A5018963320 @default.
• W1994201468 hasAuthorship W1994201468A5031742046 @default.
• W1994201468 hasAuthorship W1994201468A5032623848 @default.
• W1994201468 hasAuthorship W1994201468A5046856065 @default.
• W1994201468 hasAuthorship W1994201468A5046945534 @default.
• W1994201468 hasAuthorship W1994201468A5053058017 @default.
• W1994201468 hasAuthorship W1994201468A5063978497 @default.
• W1994201468 hasAuthorship W1994201468A5077517566 @default.
• W1994201468 hasConcept C126322002 @default.
• W1994201468 hasConcept C156957248 @default.
• W1994201468 hasConcept C164705383 @default.
• W1994201468 hasConcept C168563851 @default.
• W1994201468 hasConcept C23131810 @default.
• W1994201468 hasConcept C2777565915 @default.
• W1994201468 hasConcept C2780400711 @default.
• W1994201468 hasConcept C44249647 @default.
• W1994201468 hasConcept C45393284 @default.
• W1994201468 hasConcept C500558357 @default.
• W1994201468 hasConcept C71924100 @default.
• W1994201468 hasConceptScore W1994201468C126322002 @default.
• W1994201468 hasConceptScore W1994201468C156957248 @default.
• W1994201468 hasConceptScore W1994201468C164705383 @default.
• W1994201468 hasConceptScore W1994201468C168563851 @default.
• W1994201468 hasConceptScore W1994201468C23131810 @default.
• W1994201468 hasConceptScore W1994201468C2777565915 @default.
• W1994201468 hasConceptScore W1994201468C2780400711 @default.
• W1994201468 hasConceptScore W1994201468C44249647 @default.
• W1994201468 hasConceptScore W1994201468C45393284 @default.
• W1994201468 hasConceptScore W1994201468C500558357 @default.
• W1994201468 hasConceptScore W1994201468C71924100 @default.
• W1994201468 hasIssue "4" @default.
• W1994201468 hasLocation W19942014681 @default.
• W1994201468 hasLocation W19942014682 @default.
• W1994201468 hasOpenAccess W1994201468 @default.
• W1994201468 hasPrimaryLocation W19942014681 @default.
• W1994201468 hasRelatedWork W193640619 @default.
• W1994201468 hasRelatedWork W2127687375 @default.
• W1994201468 hasRelatedWork W2355614377 @default.
• W1994201468 hasRelatedWork W2375584960 @default.
• W1994201468 hasRelatedWork W2378890344 @default.
• W1994201468 hasRelatedWork W2782203991 @default.

• next